Loading
NASDAQHealthcareBiotechnology
Latest quote
$28.65
+$3.79 · +15.25%
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Previous close
$28.65
+$3.79 · +15.25%
Regular session · ET · Market data may be delayed.
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Day range
Current $28.65
52-week range
Current $28.65
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
39
Expensive
Sentiment
70
Bullish
Risk
48
Elevated Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Day range
Current $28.65
52-week range
Current $28.65
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 102.93M USD | 80.08M USD | 62.52M USD | 43.01M USD | 20.64M USD |
| Selling, general, and administrative | 29.83M USD | 24.1M USD | 17.43M USD | 15.92M USD | 5.65M USD |
| Operating expenses | 132.76M USD | 104.18M USD | 79.95M USD | 58.93M USD | 26.29M USD |
| Interest income | 12.82M USD | 17.7M USD | 10.81M USD | 3.65M USD | 13K USD |
| Depreciation and amortization | 546K USD | 519K USD | 357K USD | 296K USD | 140K USD |
| Operating income | −132.76M USD | −104.18M USD | −79.95M USD | −58.93M USD | −26.29M USD |
| Net income | −119.95M USD | −86.48M USD | −69.13M USD | −55.33M USD | −26.29M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$48.00
67.54% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
